Remark: The balance of net bene t from long-term oral anticoagulation might be more favorable in those with deep ICH or without neuroimaging evidence of cerebral amyloid angiopathy. Remark: In ICH survivors with AF, clinicians should aim to estimate the risk of recurrent ICH (using ICH location and, where available, MRI biomarkers including cerebral microbleeds) and the risk of ischemic stroke. Remark: The optimal timing of anticoagulation after ICH is not known, but should be delayed beyond the acute phase (approximately 48 h) and probably for at least approximately 4 weeks. Randomized trials of NOACs and left atrial appendage occlusion are ongoing. 38. In ICH survivors at high risk of recurrent ICH (eg, those with probable cerebral amyloid angiopathy), we suggest left atrial appendage occlusion (Ungraded consensus-based statement). Remark: Cerebral amyloid angiopathy should be diagnosed using validated clinico-radiological criteria. 39. In patients with AF and symptomatic carotid stenosis (> 50%), we suggest carotid revascularization with endarterectomy or stenting in addition to OAC as indicated (Weak recommendation, moderate quality evidence). 40. In patients with AF and carotid stenosis treated with revascularization, we suggest OAC therapy, without long-term antiplatelet therapy (Ungraded consensus-based statement). Remark: There is limited evidence to guide the optimal treatment of patients with AF and carotid stenosis not requiring revascularization. Remark: Short-term concomitant antiplatelet therapy (dual or mono) is generally used in the immediate post- revascularization period (eg, 1-3 months). 1126 Evidence-Based Medicine [ 1 5 4 # 5 C H E S T N O V E M B E R 2 0 1 8 ] 41. 